Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-05-16

Clinical Trial Update: An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738) [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for verubecestat (MK-8931) in mild to moderate Alzheimer's disease showing termination with posted results in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Verubecestat (MK-8931)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Alzheimer's Disease | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2018-05-16